Distinguishing among incretin-based therapies. Introduction
The "treat to target" approach is to quickly achieve the target glycosylated hemoglobin (AIC) goal of
Gespeichert in:
| Veröffentlicht in: | The Journal of family practice 2010-09, Vol.59 (9 Suppl 1), p.S3-S4 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S4 |
|---|---|
| container_issue | 9 Suppl 1 |
| container_start_page | S3 |
| container_title | The Journal of family practice |
| container_volume | 59 |
| creator | Campbell, R Keith Cobble, Michael E Reid, Timothy S Shomali, Mansur E |
| description | The "treat to target" approach is to quickly achieve the target glycosylated hemoglobin (AIC) goal of |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_755186948</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>755186948</sourcerecordid><originalsourceid>FETCH-LOGICAL-p558-5e1d7f5fce815715fafbb8959c326e5e01281d7e1746b8042b950b8c38bd9d553</originalsourceid><addsrcrecordid>eNo1j0tLAzEUhYMgbW39CzI7VyN53UmCK6mvQsFN90Med2xkXiYzC_-9A9bN-eDwceBckQ0DIUrFjVyTm5y_KGVCMbkia041l1zoDXl8jnmK_ecc83lBYbthydj7hEtdOpsxFNMZkx0j5ofi0E9pCLOf4tDvyHVj24y3F27J6fXltH8vjx9vh_3TsRwBdAnIgmqg8agZKAaNbZzTBowXvEJAyrheDGRKVk5TyZ0B6rQX2gUTAMSW3P_Njmn4njFPdRezx7a1PQ5zrhUA05WRejHvLubsOgz1mGJn00_9f1f8Ah5JT_0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>755186948</pqid></control><display><type>article</type><title>Distinguishing among incretin-based therapies. Introduction</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Campbell, R Keith ; Cobble, Michael E ; Reid, Timothy S ; Shomali, Mansur E</creator><creatorcontrib>Campbell, R Keith ; Cobble, Michael E ; Reid, Timothy S ; Shomali, Mansur E</creatorcontrib><description>The "treat to target" approach is to quickly achieve the target glycosylated hemoglobin (AIC) goal of <7% in most people, and then intensify or change therapy as needed to maintain glycemic control. Results of an online survey demonstrate uncertainty regarding the clinical differences between glucagon-like peptide (GLP-1) agonists and dipeptidyl peptidase (DPP)-4 inhibitors. The increasingly important roles of the GLP-1 agonists and DPP-4 inhibitors stem from their overall good efficacy and safety profiles compared with other treatment options.</description><identifier>EISSN: 1533-7294</identifier><identifier>PMID: 20824238</identifier><language>eng</language><publisher>United States</publisher><subject>Adamantane - analogs & derivatives ; Adamantane - therapeutic use ; Blood Glucose - drug effects ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - physiopathology ; Dipeptides - therapeutic use ; Dipeptidyl-Peptidase IV Inhibitors - administration & dosage ; Dipeptidyl-Peptidase IV Inhibitors - adverse effects ; Dipeptidyl-Peptidase IV Inhibitors - therapeutic use ; Drug Administration Schedule ; Gastric Inhibitory Polypeptide - metabolism ; Glucagon-Like Peptide 1 - analogs & derivatives ; Glucagon-Like Peptide 1 - therapeutic use ; Glucagon-Like Peptide-1 Receptor ; Humans ; Hypoglycemic Agents - administration & dosage ; Hypoglycemic Agents - adverse effects ; Hypoglycemic Agents - therapeutic use ; Incretins - pharmacokinetics ; Incretins - pharmacology ; Incretins - therapeutic use ; Insulin - metabolism ; Insulin Resistance ; Insulin-Secreting Cells - physiology ; Liraglutide ; Metformin - therapeutic use ; Peptides - therapeutic use ; Pyrazines - therapeutic use ; Receptors, Glucagon ; Sitagliptin Phosphate ; Triazoles - therapeutic use ; Venoms - therapeutic use</subject><ispartof>The Journal of family practice, 2010-09, Vol.59 (9 Suppl 1), p.S3-S4</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20824238$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Campbell, R Keith</creatorcontrib><creatorcontrib>Cobble, Michael E</creatorcontrib><creatorcontrib>Reid, Timothy S</creatorcontrib><creatorcontrib>Shomali, Mansur E</creatorcontrib><title>Distinguishing among incretin-based therapies. Introduction</title><title>The Journal of family practice</title><addtitle>J Fam Pract</addtitle><description>The "treat to target" approach is to quickly achieve the target glycosylated hemoglobin (AIC) goal of <7% in most people, and then intensify or change therapy as needed to maintain glycemic control. Results of an online survey demonstrate uncertainty regarding the clinical differences between glucagon-like peptide (GLP-1) agonists and dipeptidyl peptidase (DPP)-4 inhibitors. The increasingly important roles of the GLP-1 agonists and DPP-4 inhibitors stem from their overall good efficacy and safety profiles compared with other treatment options.</description><subject>Adamantane - analogs & derivatives</subject><subject>Adamantane - therapeutic use</subject><subject>Blood Glucose - drug effects</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - physiopathology</subject><subject>Dipeptides - therapeutic use</subject><subject>Dipeptidyl-Peptidase IV Inhibitors - administration & dosage</subject><subject>Dipeptidyl-Peptidase IV Inhibitors - adverse effects</subject><subject>Dipeptidyl-Peptidase IV Inhibitors - therapeutic use</subject><subject>Drug Administration Schedule</subject><subject>Gastric Inhibitory Polypeptide - metabolism</subject><subject>Glucagon-Like Peptide 1 - analogs & derivatives</subject><subject>Glucagon-Like Peptide 1 - therapeutic use</subject><subject>Glucagon-Like Peptide-1 Receptor</subject><subject>Humans</subject><subject>Hypoglycemic Agents - administration & dosage</subject><subject>Hypoglycemic Agents - adverse effects</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Incretins - pharmacokinetics</subject><subject>Incretins - pharmacology</subject><subject>Incretins - therapeutic use</subject><subject>Insulin - metabolism</subject><subject>Insulin Resistance</subject><subject>Insulin-Secreting Cells - physiology</subject><subject>Liraglutide</subject><subject>Metformin - therapeutic use</subject><subject>Peptides - therapeutic use</subject><subject>Pyrazines - therapeutic use</subject><subject>Receptors, Glucagon</subject><subject>Sitagliptin Phosphate</subject><subject>Triazoles - therapeutic use</subject><subject>Venoms - therapeutic use</subject><issn>1533-7294</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1j0tLAzEUhYMgbW39CzI7VyN53UmCK6mvQsFN90Med2xkXiYzC_-9A9bN-eDwceBckQ0DIUrFjVyTm5y_KGVCMbkia041l1zoDXl8jnmK_ecc83lBYbthydj7hEtdOpsxFNMZkx0j5ofi0E9pCLOf4tDvyHVj24y3F27J6fXltH8vjx9vh_3TsRwBdAnIgmqg8agZKAaNbZzTBowXvEJAyrheDGRKVk5TyZ0B6rQX2gUTAMSW3P_Njmn4njFPdRezx7a1PQ5zrhUA05WRejHvLubsOgz1mGJn00_9f1f8Ah5JT_0</recordid><startdate>201009</startdate><enddate>201009</enddate><creator>Campbell, R Keith</creator><creator>Cobble, Michael E</creator><creator>Reid, Timothy S</creator><creator>Shomali, Mansur E</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201009</creationdate><title>Distinguishing among incretin-based therapies. Introduction</title><author>Campbell, R Keith ; Cobble, Michael E ; Reid, Timothy S ; Shomali, Mansur E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p558-5e1d7f5fce815715fafbb8959c326e5e01281d7e1746b8042b950b8c38bd9d553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adamantane - analogs & derivatives</topic><topic>Adamantane - therapeutic use</topic><topic>Blood Glucose - drug effects</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - physiopathology</topic><topic>Dipeptides - therapeutic use</topic><topic>Dipeptidyl-Peptidase IV Inhibitors - administration & dosage</topic><topic>Dipeptidyl-Peptidase IV Inhibitors - adverse effects</topic><topic>Dipeptidyl-Peptidase IV Inhibitors - therapeutic use</topic><topic>Drug Administration Schedule</topic><topic>Gastric Inhibitory Polypeptide - metabolism</topic><topic>Glucagon-Like Peptide 1 - analogs & derivatives</topic><topic>Glucagon-Like Peptide 1 - therapeutic use</topic><topic>Glucagon-Like Peptide-1 Receptor</topic><topic>Humans</topic><topic>Hypoglycemic Agents - administration & dosage</topic><topic>Hypoglycemic Agents - adverse effects</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Incretins - pharmacokinetics</topic><topic>Incretins - pharmacology</topic><topic>Incretins - therapeutic use</topic><topic>Insulin - metabolism</topic><topic>Insulin Resistance</topic><topic>Insulin-Secreting Cells - physiology</topic><topic>Liraglutide</topic><topic>Metformin - therapeutic use</topic><topic>Peptides - therapeutic use</topic><topic>Pyrazines - therapeutic use</topic><topic>Receptors, Glucagon</topic><topic>Sitagliptin Phosphate</topic><topic>Triazoles - therapeutic use</topic><topic>Venoms - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Campbell, R Keith</creatorcontrib><creatorcontrib>Cobble, Michael E</creatorcontrib><creatorcontrib>Reid, Timothy S</creatorcontrib><creatorcontrib>Shomali, Mansur E</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of family practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Campbell, R Keith</au><au>Cobble, Michael E</au><au>Reid, Timothy S</au><au>Shomali, Mansur E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Distinguishing among incretin-based therapies. Introduction</atitle><jtitle>The Journal of family practice</jtitle><addtitle>J Fam Pract</addtitle><date>2010-09</date><risdate>2010</risdate><volume>59</volume><issue>9 Suppl 1</issue><spage>S3</spage><epage>S4</epage><pages>S3-S4</pages><eissn>1533-7294</eissn><abstract>The "treat to target" approach is to quickly achieve the target glycosylated hemoglobin (AIC) goal of <7% in most people, and then intensify or change therapy as needed to maintain glycemic control. Results of an online survey demonstrate uncertainty regarding the clinical differences between glucagon-like peptide (GLP-1) agonists and dipeptidyl peptidase (DPP)-4 inhibitors. The increasingly important roles of the GLP-1 agonists and DPP-4 inhibitors stem from their overall good efficacy and safety profiles compared with other treatment options.</abstract><cop>United States</cop><pmid>20824238</pmid></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1533-7294 |
| ispartof | The Journal of family practice, 2010-09, Vol.59 (9 Suppl 1), p.S3-S4 |
| issn | 1533-7294 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_755186948 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adamantane - analogs & derivatives Adamantane - therapeutic use Blood Glucose - drug effects Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - physiopathology Dipeptides - therapeutic use Dipeptidyl-Peptidase IV Inhibitors - administration & dosage Dipeptidyl-Peptidase IV Inhibitors - adverse effects Dipeptidyl-Peptidase IV Inhibitors - therapeutic use Drug Administration Schedule Gastric Inhibitory Polypeptide - metabolism Glucagon-Like Peptide 1 - analogs & derivatives Glucagon-Like Peptide 1 - therapeutic use Glucagon-Like Peptide-1 Receptor Humans Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - adverse effects Hypoglycemic Agents - therapeutic use Incretins - pharmacokinetics Incretins - pharmacology Incretins - therapeutic use Insulin - metabolism Insulin Resistance Insulin-Secreting Cells - physiology Liraglutide Metformin - therapeutic use Peptides - therapeutic use Pyrazines - therapeutic use Receptors, Glucagon Sitagliptin Phosphate Triazoles - therapeutic use Venoms - therapeutic use |
| title | Distinguishing among incretin-based therapies. Introduction |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T01%3A51%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Distinguishing%20among%20incretin-based%20therapies.%20Introduction&rft.jtitle=The%20Journal%20of%20family%20practice&rft.au=Campbell,%20R%20Keith&rft.date=2010-09&rft.volume=59&rft.issue=9%20Suppl%201&rft.spage=S3&rft.epage=S4&rft.pages=S3-S4&rft.eissn=1533-7294&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E755186948%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=755186948&rft_id=info:pmid/20824238&rfr_iscdi=true |